Topic summary

State-level differences that actually matter

Regional › North America compounding telehealth insurance FDA Solved

This is a generated summary. It shows the 5 most-liked posts from a topic of 11, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

g.valckenaereTL3Regular5 May 2025 · edited#4

The number people quote for state-level differences is a central estimate presented without its interval, and the interval is wide enough that the estimate is nearly uninformative on its own.

27 likes 15mo

g.ekstromTL2 Solution30 May 2025#5

Before the thread moves on from state-level differences — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from an n of four and from an n of four hundred.

9 likes 14mo

n.serranoTL214 Jul 2025#7

s.roos, post #3: Post #2 is right about the mechanism and I think understates the practical bit. Cost comparisons should state whether they include the device and the dispensing fee, because those differ between routes and between states. Go to post

Post #5 answers the question as asked. The question underneath it is different.

The public assessment documents published at approval are free, detailed and largely unread here.

I am describing what is, rather than arguing for what should be.

19 likes in reply to #3 12mo

ni.stanescuTL225 Aug 2025#9

This follows post #7 rather than contradicting it.

One caution on state-level differences: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated.

14 likes in reply to #3 11mo

ambient_reviewTL3Regular14 Sep 2025#10

BBramley, post #6: Clear enough that I do not think I have a follow-up, which is unusual. Go to post

I read post #9 twice before replying, because I had assumed the opposite.

Pharmacy practice varies between pharmacies within the same city, so two honest accounts can be entirely different.

28 likes in reply to #6 10mo

Read the full topic (11 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
About the North America category Regional › North America FDA compounding insurance Pinned Wiki US and Canadian regulation, compounding, and coverage. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a note. If the scope…	+3	7	43k	9mo
Coverage in the US: a map of the usual obstacles Regional › North America FDA insurance telehealth compounding Coverage in the US: a map of the usual obstacles — setting out what I have, and where I think it stops being reliable. Trying to establish the boundary conditions on coverage. The general claim is fine; I…	+46	50	7.9k	5mo
[2026 update] US compounding rules and how they changed Regional › North America FDA compounding insurance Solved US compounding rules and how they changed Writing it up because I had to work it out twice and would rather nobody else did. Regional question, dated January 2026, because everything in this category expires.…	+32	37	7.4k	10mo
Canadian access and provincial variation — one year on Regional › North America FDA compounding insurance Canadian access and provincial variation — one year on Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about Canadian access and provincial variation…	+43	47	964	12mo
US compounding rules and how they changed Regional › North America FDA telehealth insurance Closed US compounding rules and how they changed — setting out what I have, and where I think it stops being reliable. Reporting a regional experience with the date and the jurisdiction attached, because an undated…	+62	68	1.4k	20mo

Related topics — sharing the tags compounding, telehealth, insurance

Topic	Participants	Replies	Views	Activity
[2026 update] Availability by country, dated, with primary sources Access › International MHRA NHS telehealth personal import On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…	+40	45	14k	4mo
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Sourcing › Regulatory FDA EMA compounding research use only Closed On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion. I would like to know what people here actually do…	+76	82	52k	11mo
[2026 update] Travelling with an injectable: documentation and practicalities Access › International telehealth EMA MHRA NHS Travelling with an injectable: documentation and practicalities Writing it up because I had to work it out twice and would rather nobody else did. Dated regional question, February 2026, because everything in…	+107	111	12k	1d
Second pass at: Manufacturer assistance programmes and their eligibility rules Access › Pricing cost per milligram data table compounding formulary Second pass at: Manufacturer assistance programmes and their eligibility rules — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on…	+13	17	1.8k	16mo
Follow-up: State-level differences that actually matter Regional › North America FDA telehealth insurance State-level differences that actually matter — setting out what I have, and where I think it stops being reliable. A follow-up question about State-level differences that I did not know to ask the first time.…	+90	96	4.1k	4mo